PHope is a transseptal bi-atrial cannula that restores the natural blood flow to the body during ECMO while reducing complications associated with traditional methods.
Unlike traditional ECMO cannulas, P-Hope:
Fully unloads the right ventricle and lungs, allowing them time to rest and heal.
Effectively delivers oxygenated blood to the brain, heart and upper limbs.
Reduces the need for invasive surgery for left-ventricular venting.
Lowers the risk of infection while encouraging ambulation and rehab participation.
-
Expected De Novo approval.
-
Utility patents filed and under review in the US and EU with 2021 priority dates. In 2025, an additional provisional patent was filed.
-
PHope has undergone multiple prototype iterations and preclinical studies. We anticipate a final chronic pre-clinical study and IDE in 2026.
Interested in this technology? Let’s connect.
Contact zane@waterstoncapital.com
How It Works
P-Hope drains deoxygenated blood from the right atrium via its outer lumen, transports it to the ECMO machine for oxgenation, and returns oxygenated blood directly to the left atrium via its inner lumen. A balloon- anchoring system secures P-Hope across the septum. Real-time adjustments via atrial pressure sensors reduce risk of LV overload. Jugular insertion reduces the risk of infection compared to a femoral approach and encourages ambulation and participation in rehab.
Who Benefits
The P-Hope Cannula is designed for
Naïve patients who present acutely with Right Heart Failure (RHF).
Those with refractory or recurrent RHF who are eligible for lung transplant (bridge to transplant), and those needing time for medical optimization (bridge to recovery).
PAH patients groups 1, 3, 4.
Those with ARDS.